ロード中...
Composite cognitive and functional measures for early stage Alzheimer's disease trials
INTRODUCTION: Composite scales have been advanced as primary outcomes in early stage Alzheimer's disease trials, and endorsed by the U.S. Food and Drug Administration (FDA) for pivotal trials. They are generally composed of several neurocognitive subscales and may include clinical and functiona...
保存先:
| 出版年: | Alzheimers Dement (Amst) |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7233425/ https://ncbi.nlm.nih.gov/pubmed/32432155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/dad2.12017 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|